All News
Oral IL-23 Inhibitor Effective in Psoriasis
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
https://t.co/NRK8LnM5zp https://t.co/FnWEze976O
Dr. John Cush RheumNow ( View Tweet)
Tonix is developing a drug, TNX-102 SL, that targets poor sleep quality for fibromyalgia. Phase 3 trial in FM (457 pts) showed TNX-102 SL was better (vs PBO) & improved sleep quality (p=0.0000001 & improved daily pain (p=0.00005) https://t.co/QUNdWyNj2l https://t.co/CzD5TEcgTk
Dr. John Cush RheumNow ( View Tweet)
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/bAZ8m3OBo2 https://t.co/SlneyfbJIh
Dr. John Cush RheumNow ( View Tweet)
Curbside Consults (2.16.2024)
Dr. Jack Cush answers audience clinical case questions sent by email or "ask Cush anything". Cases and questions from:
Read Article
Beautiful graphic from Lyu X describing CAR-T development/manufacturing. Dr. @susanshenoi #RWCS24 @RheumNow @RWCSmtg https://t.co/yujfZeBaW7
Dr. Rachel Tate uptoTate ( View Tweet)
Hot off the press! Case report inspired by Dr. George Martin. Topical ruxolitinib efficacy in cutaneous DM. Dr. @susanshenoi #RWCS24 @RWCSmtg @RheumNow https://t.co/uyJdvgJ0ue
Dr. Rachel Tate uptoTate ( View Tweet)
Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf
Dr. John Cush RheumNow ( View Tweet)
"It's hard not to be jealous of the dermatologists." @JointMD discussing the results of JNJ 77242113, po IL-23R, the Frontier 1 trial. #RWCS24 @RWCSmtg @RheumNow https://t.co/1zQ6bu5TM2
Dr. Rachel Tate uptoTate ( View Tweet)
Combo IL-23 and TNFi synergistic benefit in UC in the proof-of-concept VEGA trial. More data to come! #RWCS24 @RWCSmtg @RheumNow https://t.co/FgLTR2PBYJ
Dr. Rachel Tate uptoTate ( View Tweet)
APIPPRA Trial: Abatacept in at-risk rheumatoid arthritis patients
Abatacept has been studied in seropositive clinically suspect arthralgia patients (at risk for rheumatoid arthritis) and shows the potential to delay or prevent the disease.
Read Article
Sex Disparities in PsA/SpA
Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.
Read Article
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/cOeg3KL8Z3 https://t.co/pPRqD7PkXB
Dr. John Cush RheumNow ( View Tweet)
J&J announced the results of Phase 2 DAHLIAS study of nipocalimab in Sjögren’s; w/ a signif reduction in clinESSDAI at week 24 vs placebo. Nipocalimab is an investigational anti-FcRn treatment being studied in RA, & myasthenia gravis https://t.co/mroLPx0BnH https://t.co/7IqlY1K6di
Dr. John Cush RheumNow ( View Tweet)
VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read Article
Many #RA pts remain on Steroids despite b/tsDMARD use! Study 228 #RA pts, 68% Rx low-dose GCs (32% no GCs). After 3 yrsof b/tsDMARDs, 32% still on GCs, 23% D/C GCs, & 20% go on & off, 25% never took GCs. GCs use assoc w/ HTN (20 v 11%) & MI (2.3% vs 0) https://t.co/lWVfvJrAyp https://t.co/uTIWqDAjRG
Dr. John Cush RheumNow ( View Tweet)
Pre-Treatment Testing with Biologics Falls Short
US commercial insurance claim analysis of lab screening and monitoring practices in CISD patients shows that < 60% received the reco pretreatment testing when starting systemic immunomodulatory treatment.
https://t.co/WdI3xfMyng https://t.co/xxKVkag60o
Dr. John Cush RheumNow ( View Tweet)
Dupilumab (IL-4/13 Inhib) may cause MSK Sxs. Study of 470 Atopic Dermatitis pts on dupilumab; 36 referred to rheum consult, 26 pts (14M/12F) had US/MRI proven enthesitis, arthritis, or tenosynovitis (16 mild, 4 severe). All responded to NSAID or DUP D/C https://t.co/S3ACOC4xUZ https://t.co/juAYbIxNZ6
Dr. John Cush RheumNow ( View Tweet)
Rituximab is superior to cyclophosphamide in relapsing AAV. Provided you are relapsing after having cyclophosphamide as your first agent of course... @EBRheum @RheumNow #RNL2024 https://t.co/JfbcKH2zCG
Richard Conway RichardPAConway ( View Tweet)
Remission maintenance in AAV. First 2 years is clear - fixed dose RTX is superior. After that it is clear that following ANCA is suboptimal, could consider either B-cell return dosing or ongoing fixed dosing @anisha_dua @RheumNow #RNL2024 https://t.co/0Elir88L9U
Richard Conway RichardPAConway ( View Tweet)
Rheumatology drugs in pregnancy. Just missing leflunomide in that big no no section @DrCassySims @RheumNow #RNL2024 https://t.co/ZPtTGRqPki
Richard Conway RichardPAConway ( View Tweet)